Maven Securities LTD Regeneron Pharmaceuticals, Inc. Transaction History

Maven Securities LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$775.18 - $881.7 $318,598 - $362,378	411 Added 141.24%	702 $616,000
Q3 2023 Nov 13, 2023	BUY	$692.45 - $844.37 $201,502 - $245,711	291 New	291 $239,000
Q2 2022 Aug 15, 2022	BUY	$548.35 - $738.84 $445,260 - $599,938	812 Added 190.61%	1,238 $732,000
Q1 2022 May 16, 2022	BUY	$595.12 - $698.43 $15,473 - $18,159	26 Added 6.5%	426 $298,000
Q4 2021 Feb 14, 2022	BUY	$543.48 - $670.97 $217,392 - $268,388	400 New	400 $253,000
Q2 2021 Aug 16, 2021	SELL	$472.8 - $558.54 $245,856 - $290,440	-520 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$446.73 - $548.2 $481,574 - $590,959	-1,078 Reduced 67.46%	520 $246,000
Q4 2020 Feb 12, 2021	BUY	$478.3 - $607.98 $294,632 - $374,515	616 Added 62.73%	1,598 $772,000
Q3 2020 Nov 13, 2020	BUY	$544.75 - $658.21 $332,297 - $401,508	610 Added 163.98%	982 $557,000
Q2 2020 Aug 14, 2020	BUY	$493.32 - $643.92 $183,515 - $239,538	372 New	372 $232,000

1,534

83.6M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $75.2B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

Stay updated on Maven Securities LTD with notifications on news.